title: Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age.
abstract: The safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate (PRP-T) administered concurrently in separate sites or mixed in the same syringe with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine were assessed in 439 infants at 2, 4 and 6 months of age. The proportions with local redness, tenderness and swelling in the separate and combined groups were 18% vs. 11% (P < 0.001), 27% vs. 24% and 15% vs. 13%, respectively. Systemic reactions occurred at similar rates in both groups. The combined vaccine induced tetanus and diphtheria antitoxin titers > or = 0.01 IU/ml in 99.5 and 99.1% of infants, pertussis agglutinin titers > or = 64 in 92.4%, anti-polyribosylribitol phosphate titers > or = 0.15 microgram/ml in 93.8% and > or = 1.0 microgram/ml in 75% and polio-neutralizing titers > or = 8 in > 98% of infants. However, antibody concentrations to PRP-T, some pertussis antigens and tetanus toxoid were significantly lower after combined than after separate injections of DPT/diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine and PRP-T. The clinical significance of these differences is not known, but the interactions observed among the components of the pentavalent vaccine may be of concern because they might influence antibody persistence until the fourth dose is administered.
authors.affiliation: Division of Infectious Diseases, Hospital for Sick Children, Toronto, Ontario, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: D
authors.initials: D
authors.lastname: Scheifele
authors.forename: L
authors.initials: L
authors.lastname: Barreto
authors.forename: S
authors.initials: S
authors.lastname: Wiltsey
authors.forename: G
authors.initials: G
authors.lastname: Bjornson
authors.forename: W
authors.initials: W
authors.lastname: Meekison
authors.forename: R
authors.initials: R
authors.lastname: Guasparini
authors.forename: L
authors.initials: L
authors.lastname: Medd
mesh_terms: D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects* / Q000276:immunology; D018073:Haemophilus Vaccines / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007223:Infant; D011054:Poliovirus Vaccine, Inactivated / Q000009:adverse effects* / Q000276:immunology; D013745:Tetanus Toxoid / Q000009:adverse effects* / Q000276:immunology; D014611:Vaccination; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; C055753:Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate; D011054:Poliovirus Vaccine, Inactivated; D013745:Tetanus Toxoid; D017778:Vaccines, Combined; D018074:Vaccines, Conjugate